home About Us People Portfolio News Contact Us Fund II Investor Login » Fund III Investor Login » Fund IV Investor Login »

NanoString Technologies

« Back to company
Press Releases

$80 million

Tools & Diagnostics
Research Oncology

NanoString Technologies Announces Pricing of Upsized Offering of $200 Million of Convertible Senior Notes »

NanoString Technologies Announces Pricing of Public Offering of 4,500,000 Shares of Common Stock »

NanoString Announces $100 Million Term Loan Facility with CRG »

NanoString Technologies Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock »

Humana Issues Positive Coverage Decision for NanoString's Prosigna® Breast Cancer Assay »

Cigna Issues Positive Coverage Decision for NanoString's Prosigna® Breast Cancer Assay »

Aetna Issues Positive Coverage Decision for NanoString's Prosigna® Breast Cancer Assay »

NanoString Technologies Enters Into Collaboration Agreement With Medivation and Astellas to Develop Novel Companion Diagnostic Test »

NanoString Technologies Expands 3D Biology Portfolio With the Commercial Launch of Seven New nCounter PanCancer Profiles to Deeply Probe Cancer Biology »

NanoString Technologies Expands Immuno-Oncology Portfolio With Commercial Launch of Innovative nCounter RNA:Protein PanCancer Immune Profiling Panel »

ESMO Clinical Practice Guidelines for Breast Cancer Recommend the Use of Prosigna/PAM50 Assay for Determining Potential Benefit From Chemotherapy »

NanoString Technologies Receives Favorable Final Local Coverage Determination by Palmetto GBA for Its Prosigna Breast Cancer Assay »

NCCN Clinical Practice Guidelines for Breast Cancer Acknowledge Prosigna/PAM50 as Clinically Validated for Prediction of Prognosis »

NanoString Technologies Launches New nCounter SPRINT(TM) Profiler Designed to Meet Needs of the Individual Researcher »

Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab) »

St. Gallen International Breast Cancer Guidelines Recognize Power of Prosigna/PAM50 to Inform Treatment Decisions and Spare Low Risk Breast Cancer Patients Unnecessary Chemotherapy »

NanoString Technologies Empowers Cancer Researchers With Three Innovative New Products for the nCounter Analysis System »

Introduction of RNA: Protein Profiling Panel Focused on Immuno-Oncology Addresses the Next Generation of Tumor Profiling


Launch of Two New PanCancer Gene Expression Panels Strengthens Portfolio of Tools to Thoroughly Analyze the Hallmarks of Cancer and Expands Offerings in Immuno-Oncology 


Seattle, April 16, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of its rapidly growing product portfolio focused on cutting edge genomic—and now proteomic—cancer research with the introduction of three new products for the nCounter® Analysis System. These products include the Immuno-Oncology RNA:Protein Profiling Panel, a single assay that enables simultaneous analysis of gene and protein expression, the PanCancer Progression Panel, and the PanCancer Mouse Immune Profiling Panel.


"The introduction of these new products builds on our plan to make the nCounter Analysis System an indispensable tool for tumor profiling by providing researchers with a comprehensive view of cancer biology," said Brad Gray, President and Chief Executive Officer of NanoString Technologies. "Our revolutionary approach to the simultaneous analysis of gene and protein expression will now allow our research customers to capture even more biology from their precious tumor samples, leading to a better understanding of new therapeutic approaches, including immuno-oncology."


The RNA:Protein profiling assay represents an entirely new category of multiplexed digital counting addressing the next generation of tumor profiling experiments. The assay enables simultaneous measurement of up to 800 RNA and protein targets in minute cancer samples. The initial RNA:Protein offering is based on the company's popular PanCancer Immune Profiling panel, providing the measurement of 770 RNA and 30 proteins important in immuno-oncology research. Initially the product will be available to select customers participating in a product access program.


The PanCancer Progression Panel, now available to all customers, addresses the key questions of what happens when cancer metastasizes, and includes genes for the study of angiogenesis, epithelial mesenchymal transition (EMT), extracellular matrix (ECM) formation, and metastasis. Together with the company's PanCancer Pathways Panel and PanCancer Immune Profiling Panel, researchers are now able to thoroughly analyze the biological foundations of the Hallmarks of Cancer, first described in seminal papers by Hanahan and Weinberg (Hanahan, D., and Weinberg, R.A. (2000). Cell 100, 57-70 and Hanahan, D., and Weinberg, R.A. (2011). Cell 144, 646-674).


The launch also includes the new PanCancer Mouse Immune Profiling Panel, a companion product to the company's human PanCancer Immune Profiling Panel. It will provide researchers with a vital tool for pre-clinical studies in the field of immuno-oncology, enabling the study of combination therapy including mechanistic studies and toxicity.


At the 2015 AACR Annual Meeting in Philadelphia, Pennsylvania, Joe Beechem, Ph.D., Senior Vice President of Research and Development at NanoString Technologies, will provide an introduction to NanoString's RNA:Protein profiling assays. The presentation is titled "Simultaneous Multi-omic Measurement of Gene Fusions, mRNA and Proteins at 800-plex Using Single Molecule Optical Barcodes" and is scheduled for Monday, April 20 at 10:00 a.m. EDT.


About NanoString Technologies, Inc.


NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in over 700 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has now been applied to diagnostic use. The Prosigna® Breast Cancer Prognostic Gene Signature Assay, together with the nCounter Dx Analysis System, is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.


For more information, please visit www.nanostring.com.


The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.


Forward-Looking Statements


This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the scientific and medical potential of our multi-omic technology to simultaneously profile gene and protein expression, and its ability to optimize the use of new cancer therapeutics in the field of immuno-oncology. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.


CONTACT: NanoString Contact:


         Leigh Salvo of Westwicke Partners





NanoString Technologies' Prosigna Breast Cancer Assay Included in German Breast Cancer Treatment Guidelines »

NanoString Technologies Updates Prosigna FDA Labeling to Provide Greater Insight into Probability of Breast Cancer Recurrence Between Year 5 and 10 After Diagnosis »

NanoString Technologies Receives Canadian Market Approval for its Prosigna Breast Cancer Prognostic Gene Signature Assay »